Figure 4.
Therapeutic efficacy of DTX loaded liposomes in comparison with control groups (PBS, and Taxotere) in BABL/c models of 4T1 (upper panel) or TUBO (lower panel) mammary carcinoma. A: Body weight, B: Average tumor volume (mm3) in all treated groups and C: Survival of all groups was monitored. (n = 4 or 5, mean ± S.D). In 4T1 breast carcinoma tumor model, F1, F2, and F3 formulations significantly extended mouse survival compared to PBS (p < 0.01, p < 0.0, p < 0.05, respectively). Also, the overall survivals were significantly improved in mice treated with F1 liposomes compare to those received Taxotere (p < 0.05, log-rank).